Trial Profile
A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs F8 IL10 (Primary) ; Methotrexate; Methotrexate; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Philogen
- 16 Jun 2018 Updated results of Dekavil of phase 1 and phase 2 studies presented at the 19th Annual Congress of the European League Against Rheumatism.
- 08 Nov 2017 Status changed from recruiting to completed, according to the results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 08 Nov 2017 Results of phase Ib trial (NCT02076659; n=34) and the phase II trial (NCT02270632; n=23; As of May 2017), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting